Somewhat Positive News Coverage Somewhat Unlikely to Impact PhaseRx (PZRX) Stock Price
News articles about PhaseRx (NASDAQ:PZRX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PhaseRx earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1939479751076 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
- PhaseRx (PZRX) Reports Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA (streetinsider.com)
- PhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European Union (finance.yahoo.com)
- PHASERX, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency (finance.yahoo.com)
PhaseRx (NASDAQ:PZRX) traded down $0.19 during trading on Friday, reaching $0.97. 2,130,500 shares of the company traded hands, compared to its average volume of 346,936. The company has a debt-to-equity ratio of -12.03, a quick ratio of 2.14 and a current ratio of 2.14. PhaseRx has a 1-year low of $0.54 and a 1-year high of $2.67.
Separately, Laidlaw downgraded shares of PhaseRx from a “buy” rating to a “neutral” rating in a research report on Friday, October 13th.
ILLEGAL ACTIVITY WARNING: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/01/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-phaserx-pzrx-stock-price.html.
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.
Receive News & Stock Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related stocks with our FREE daily email newsletter.